Assembly Biosciences

NSQ:ASMB · US0453962070

BiotechnologySmall

360

Value44

Profit price100

Cash yield1

Owner Earnings Yield1

Dividend Yield1

Sales & asset price44

Price/Sales65

EV / Gross Profit5

Price/Book62

Quality54

Returns on capital80

Return on Capital76

Cash Return on Capital83

Return on Equity82

Profit margins45

EBIT Margin51

Gross Profitability39

Cash backing37

Accruals5

Owner Earnings Margin69

Growth52

Sales growth42

Profit growth96

Reinvestment49

Price momentum53

Safety26

Debt load81

Debt serviceability11

Refinancing21

Debt Payback1

Liquidity1

Sentiment55

Analyst ratings100

Expectations trend51

Opinion Changes50

Price Target Upside52

Market mood27

Value Creation10/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Assembly Biosciences clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Founded2005

Employees91

Websiteassemblybio.com

ISINUS0453962070

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

Infectious DiseasesHepatologyBiotechnologyHealth Care

Description

Assembly Biosciences, Inc. operates as a biotechnology company. The company’s pipeline includes multiple clinical-stage investigational therapies, including: two long-acting helicase-primase inhibitors (HPIs) for the treatment of recurrent genital h…

Analysis

Middle-of-the-road

Assembly Biosciences, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 10/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Assembly Biosciences with its peers

Precision BioSciences

NAQ:DTIL

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Gain Therapeutics

NMQ:GANX

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Atea Pharmaceuticals

NSQ:AVIR

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Oric Pharmaceuticals

NSQ:ORIC

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

PepGen

NSQ:PEPG

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

BridgeBio Oncology Therapeutics

NMQ:BBOT

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →